DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01879917

NewLira

CompletedPhase 2, PHASE3

Liraglutide in Newly Onset Type 1 Diabetes.

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Trial of Liraglutide Treatment in Subjects With Newly Diagnosed Type 1 Diabetes.

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

65

actual

Study population

Type 1 diabetes

Key I/E criterion

—

Primary endpoint

•Beta-cell function

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01879917
Org study ID2012-005317-39
Secondary IDU1111-1137-3221WHO

Timeline

Milestones

Study first posted2013-06-18estimated
Last update posted2021-03-30actual
Study start2014-02actual (month precision)
Primary completion2018-08actual (month precision)
Study completion2018-08actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 1 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age40 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Type 1 diabetes according to WHO criteria diagnosed ≤ 6 weeks before visit 0
•Age 18 - 40 years - both inclusive
•Postprandial C-peptide > 0.2 nmol/l following sustacal meal test
•Able to understand the written patient information and to give informed consent

Exclusion criteria

•Type 2 diabetes
•Body mass index <20 kg/m2
•Pregnancy or unwillingness to use safe contraceptives
•Compromised kidney function (eGFR < 60 ml/min/1,73m2), dialysis or kidney transplantation at visit 0
•Liver disease with elevated plasma alanine aminotransferase (ALT) > three times the upper limit of normal at visit 0

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
4
Weight & body composition
1
Safety / tolerability / PK
1
Other (unclassified)
1

Weight & body composition

1 endpoint
Other/protocol endpoint

Weight

Time frame:52 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

4 endpoints
Primary/protocol endpoint/low confidence

Beta-cell function

Time frame:52 weeks

change from baseline, improvement

Secondary/protocol endpoint

Postprandial glucagon

Time frame:52 weeks

change from baseline, improvement

Other/protocol endpoint

HbA1c

Time frame:52 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other/protocol endpoint

Insulin dose

Time frame:52 weeks

change from baseline, improvement

Safety / tolerability / PK

1 endpoint
Other/protocol endpoint

Hypoglycemia

Time frame:52 weeks

event count, event

Other (unclassified)

1 endpoint
Other/protocol endpoint/low confidence

Remission period

Time frame:52 weeks

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.